AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Jun 242014
 
09225-notw3-antibodycxd_17033436-350

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

A new study reveals the key role a protein plays in chronic obstructive pulmonary disease (COPD) and provides a potential lead for treating the incurable lung disease (Sci. Transl. Med. 2014, DOI: 10.1126/scitranslmed.3008074).

[+]Enlarge

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

09225-notw3-antibodycxd_17033436-350

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

Stephen L. Nishimura, a professor in the pathology department at the University of California, San Francisco, and colleagues have engineered a monoclonal antibody that prevents the activation of a destructive protein in COPD mouse models and have explored in detail how the antibody binds to its target.

Share

Sorry, the comment form is closed at this time.

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: